Dechra Acquires Zimeta® (dipyrone injection) from Elanco® Animal Health

Dechra Acquires Zimeta® (dipyrone injection) from Elanco® Animal Health

Friday, July 1, 2022

The acquisition expands Dechra’s equine portfolio into the non-steroidal anti-inflammatory category.

Dechra is pleased to announce the acquisition of Zimeta® (dipyrone injection) from Elanco® Animal Health. Zimeta is the first and only FDA-approved drug for the control of pyrexia in horses. Dechra has been distributing Zimeta in the US since January 2021 and has now acquired the registrations. Veterinary customers will not experience any change in how they order the product. Mike Eldred, President of Dechra North America, stated, “This acquisition provides veterinarians a novel fever-reducing medication as Dechra continues an aggressive equine portfolio expansion.”

Important Safety Information

As with all drugs, side effects may occur. Zimeta® (dipyrone injection) should not be given more frequently than every 12 hours due to the prolongation of prothrombin time (PT) and associated clinical signs of coagulopathy. For use in horses only. Do not use in horses with a hypersensitivity to dipyrone, horses intended for human consumption or any food producing animals, including lactating dairy animals. Not for use in humans, avoid direct contact with skin and keep out of reach of children. Care should be taken to avoid accidental self-injection and routine precautions should be used when handling and using loaded syringes as dipyrone can cause a deficiency in specific white blood cells in humans. Prior to use, horses should undergo a thorough history and physical examination by a veterinarian. Monitor for signs of abnormal bleeding and use caution in horses at risk for hemorrhage. Concurrent use with other NSAIDs, corticosteroids and drugs associated with kidney toxicity, should be avoided. Safety has not been evaluated in horses less than three years of age, horses used for breeding, or in pregnant or lactating mares. As a class, NSAIDs may be associated with gastrointestinal, kidney, and liver toxicity. The most common adverse reactions observed during clinical trials were elevated glucose conversion enzymes, decreased blood protein, gastric ulcers, inflamed or reddened lining of the right dorsal colon, and increased clotting times. Please see product insert for full prescribing information or visit

About Dechra

Dechra Veterinary Products’ equine portfolio includes Osphos® (clodronate injection), Orthokine® vet irap 10 and 60, and Osteokine® (PRP). Dechra also offers Equidone® Gel (domperidone), the Vetivex® line of parenteral fluids, Phycox® EQ joint health supplements, and a comprehensive line of topical dermatologic products. The recent additions of ProVet APC (Autologous Platelet Concentrate) system, Rompun® (xylazine injection), Butorphanol Tartrate Injection, Isoflurane, USP, and SucroMate® Equine (deslorelin acetate) further expand Dechra’s equine offerings.

For questions or further information, please contact Mike Eldred or Doug Hubert:

Mike EldredPresident, North American Operations, Dechra Veterinary Products,

Doug Hubert, Vice President, Sales and Marketing, Dechra Veterinary Products,